Get more info on this report!Pharmacodiagnostics and Personalized Medicine 2009 (Markets,Challenges, Forecasts and Key Pla...
pharmaceutical companies, and other factors. There are numerous companiesparticipating in this market and the number is gr...
CHAPTER TWO: OVERVIEW OF PHARMACODIAGNOSTICS PERSONALIZEDMEDICINE    Potential Benefits    Privacy and Public Perception  ...
The Needs of Pharma and of Diagnostic Companies     Questions Determining Pharmacodiagnostics Growing     A Partial Change...
Table 3-1: Pharmacodiagnostics Groups       Table 3-2: Examples of Inherited or Acquired Variations in Enzymes and       R...
Intl: +1.240.747.3093Fax: 240.747.3004
Upcoming SlideShare
Loading in...5
×

Pharmacodiagnostics and personalized medicine 2009 (markets, challenges, forecasts and key players)

253

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
253
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pharmacodiagnostics and personalized medicine 2009 (markets, challenges, forecasts and key players)

  1. 1. Get more info on this report!Pharmacodiagnostics and Personalized Medicine 2009 (Markets,Challenges, Forecasts and Key Players)April 1, 2009Pharmacodiagnostics are considered the pathway to what has been termed"personalized medicine," the use of molecular analysis to achieve optimum medicaloutcomes in the management of a patient’s disease or predisposition to disease. Assuch, personalized medicine promises to bring about a new standard of healthcare, withthe possiblity to increase profits, speed clinical trials, achieve better clinical results andsatisfy patients. But how can companies earn revenue in this undertaking? What are thelikely challenges for pharma companies and IVD companies? Will the current eocnomyimpact this emerging market?This report, Pharmacodiagnostics and Personalized Medicine (Markets, Challenges,Forecasts and Key Players) presents a realistic look at the promise and pitfalls ofpersonalized medicine, with important data useful for business planning and marketingefforts, including: Current Market Size for U.S. Pharmacodiagnostics Forecasted Likely and Best Case Revenue Projections to 2018. An Overview of the Concept, Past Successes and Failures. Potential Pitfalls for PM Strategies Forecasts for Pharmacodiagnostics in the U.S. Cancer Treatment Markets (by type.) Possible Cardiological and Psychiatric Treatment Markets 8 Strategic Conclusions And Implications For Entrants in this Market Profiles of Key Players in PharmacodiagnosticsPersonalized Medicine has given the diagnostics field a huge boost in terms ofpublicity/public attention, revenue potential, and investment interest. Still questions existas to how extensive such testing will be and how soon we will see its growth in clinicalapplications. There are many hurdles to be overcome, but researchers are confidentthey can be. For a thorough understanding of the impact that personalized medicinecould have on pharmaceutical and diagnostic companies, this report reviews theseimportant factors: including the key challenges new entrants need to overcome toestablish a revenue stream, genome costs, the likely Shotgun Effect onPharmaceutical product lines, the challenge of overcoming privacy concerns in thewake of the GINA legislation, competing cultures between diagnostic and
  2. 2. pharmaceutical companies, and other factors. There are numerous companiesparticipating in this market and the number is growing. As part of its unique analysis, thefollowing companies are profiled: Abbott Diagnostics Affymetrix, Inc. Agilent Althea Technologies Curidium Medica, PLC. Dako Gen Probe Genzyme Corporation Ipsogen Lipomics Osmetech Perlegen Sciences Provista Life Sciences Qiagen Singulex Theranostics Health Ventana Medical SystemsBecause of its size and influence, this report (necessarily, Kalorama believes), focuseson the U.S. market.TABLE OF CONTENTSCHAPTER ONE: EXECUTIVE SUMMARY BACKGROUND Potential Benefits of Pharmacodiagnostics Pittfalls of Personalized Medicine Market Considerations Drivers Impact of Current Economy Likely Market Potential Assumptions Need for Greater Payoff Higher Reimbursement Royalty Model Best Case Market Important Considerations Increase in Risk ‘Shotgun’ Effect? Privacy and Personalized Medicine Scope and Methodology
  3. 3. CHAPTER TWO: OVERVIEW OF PHARMACODIAGNOSTICS PERSONALIZEDMEDICINE Potential Benefits Privacy and Public Perception Biomarkers and Pharmacodiagnostics Types of BiomarkersCHAPTER THREE: APPLYING PHARMACODIAGNOSTICS Pharmacogentics and Pharmacogenomics Historical Basis Current Techniques Requirements Cost-effectiveness Applications The Cytochrome System Cancer Recent Activities in Pharmacodiagnostics Amgen UAMS Multiple Myeloma Project DAKO Assay for TOP2A GE and Eli Lilly Epigenomics and Abbott Celera and Merk bioMerieiux and Ipsen Acute Lymphoblastic Leukemia Regulatory Agencies Applications of Genome More Challenging Than Expected Cardiovascular Disease RAS polymorphisms With Drug Effectiveness Pgp Thiazide diuretics 825T allele HIT Statins Psychiatry and Pharmacogenetics/Pharmacogenomics Drug Development Rescue Is Herceptin a Paradigm? A Balancing Act between the PlayersCHAPTER FOUR: ESTIMATED MARKET POTENTIAL FORPHARMACODIAGNOSTICS On Estimating Market Potential Associated Testing
  4. 4. The Needs of Pharma and of Diagnostic Companies Questions Determining Pharmacodiagnostics Growing A Partial Change in Attitude Economic Impact New Approaches Industry Collaborations Intellectual Property Cancer Market Potential Estimate Ideal Market Potential - Cancer, Heart Disease, Psychiatric Challenges Unique to Pharmacodiagnostics Privacy Concerns Fear of Learning about Diseases Use of Remnant Samples Avoiding Pitfalls of Market Calculation Pharmacodiagnostics Not Linked to Molecular Diagnostics Demonic and SNP Analysis Considering Time of Cooperative Development Market Realities to Consider Possible Tactic: Royalty ModelCHAPTER FIVE: COMPANY SUMMARIES OVERVIEWCHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS Payoffs Who Leads and Who Follows? Risk Genome Cost Critical Shotgun Effect? Possibility of Price Increases Orphan Drug Markets Privacy Issue to Watch TABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: Likely Market Potential for Pharmacodiagnostics in the United States: 2009 - 2013 Figure 1-1: Likely Market Potential for Pharmacodiagnostics in the United States: 2009 - 2013 Figue 1-2: Best Case Market Potential: Potential for Pharmacodiagnostics in the United States: 2009 - 2013CHAPTER THREE: APPLYING PHARMACODIAGNOSTICS
  5. 5. Table 3-1: Pharmacodiagnostics Groups Table 3-2: Examples of Inherited or Acquired Variations in Enzymes and Receptors Affecting Drug Response and Toxicity Table 3-3: Frequency of Recessive Traits Table 3-4: Existing Cancer Drugs Complimentary to Pharmacodiagnostics Table 3-5: Genes Believed to Affect Cardiovascular Drug Metabolism (Drug/Drug Class, Associated Gene)CHAPTER FOUR: ESTIMATED MARKET POTENTIAL FORPHARMACODIAGNOSTICS Table 4-1: Markets for Cancer Pharmacodiagnostics if All Patients Tested, by Cancer Site (Oral, Digestive System, Respiratory System, Bones, Soft Tissue, Skin, Breast, Genital, Urinary, Eye, Brain, Endocrine, Lymphoma, Myeloma, Leukemia, Others) Figure 4-2: Markets for Cancer Pharmacodiagnostics if All Patients Tested, by Cancer Site (Oral, Digestive System, Respiratory System, Bones, Soft Tissue, Skin, Breast, Genital, Urinary, Eye, Brain, Endocrine, Lymphoma, Myeloma, Leukemia, Others) Table 4-2: The Ideal Potential Pharmacodiagnostics Markets for Therapeutics Addressing Four High-Profile Cancers: 2008 Figure 4-3: The Ideal Potential Pharmacodiagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008 Figure 4-1 Market If All Cancer Patients Tested Compared to Current Cancer Diagnostics Figure 4-3: The Ideal Pharmacodiagnostics Market (Ideal vs. Likely to Benefit) Figure 4-4: Subset of Ideal Market Likely to Benefit from Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market) Table 4-3: Market Projections for Pharmacodiagnostics in the United States: 2008 - 2018 (Realistic, Likely Potential, Hi Reimbursement, Absolute Best Case) millions Figure 4-5: Market Projection Trends for Pharmacodiagnostics* in the United States: 2008 - 2018Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2128157US: 800.298.5699UK +44.207.256.3920
  6. 6. Intl: +1.240.747.3093Fax: 240.747.3004

×